Strata Critical Medical (SRTA) Co-CEO exercises 27,778 options at $0.18

Strata Critical Medical (SRTA): Co-CEO, General Counsel, and Director Melissa M. Tomkiel exercised employee stock options and acquired 27,778 shares of Class A common stock at $0.18 per share on 11/07/2025 (transaction code M).

Rhea-AI Filing Summary

Strata Critical Medical (SRTA): Co-CEO, General Counsel, and Director Melissa M. Tomkiel exercised employee stock options and acquired 27,778 shares of Class A common stock at $0.18 per share on 11/07/2025 (transaction code M). Following the transaction, she beneficially owns 1,400,420 shares, held directly.

The exercised options relate to grants first exercisable on 05/07/2021 and expiring on 07/28/2030. After this activity, 276,960 stock options remain beneficially owned, held directly.

Insider Trade Summary

27,778 shares exercised/converted

Exercise 2 txns

Insider Tomkiel Melissa M.

Role Co-CEO and General Counsel

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	27,778	$0.00	$0.00
Exercise	Class A common stock, $0.0001 par value per share	27,778	$0.18	$5K

Holdings After Transaction: Stock Option (right to buy) — 276,960 contracts (Direct); Class A common stock, $0.0001 par value per share — 1,400,420 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did SRTA’s insider report in this Form 4?

Melissa M. Tomkiel exercised stock options and acquired 27,778 shares at $0.18 on 11/07/2025.

How many SRTA shares does the insider own after the transaction?

She beneficially owns 1,400,420 shares, held directly, following the reported transaction.

What was the exercise price of the SRTA options?

The exercise price was $0.18 per share.

How many SRTA options remain after the exercise?

After the transaction, 276,960 stock options remain beneficially owned, held directly.

What roles does the reporting person hold at SRTA?

She is a Director and serves as Co‑CEO and General Counsel.

What were the option grant dates for exercisability and expiration?

Options were first exercisable on 05/07/2021 and expire on 07/28/2030.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/12/2025 - 04:20 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tomkiel Melissa M.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	11/07/2025		M		27,778	A	$0.18	1,400,420	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.18	11/07/2025		M			27,778	05/07/2021	07/28/2030	Class A common stock, $0.0001 par value per share	27,778	$0	276,960	D

Explanation of Responses:

Remarks:

	/s/ Melissa M. Tomkiel	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.